TearClear: TearClear announces the successful initiation of its TC-002 Latanoprost Ophthalmic Solution Phase 3 trial

BOSTON, Feb. 07, 2022 (GLOBE NEWSWIRE) -- TearClear, a late clinical stage ophthalmic pharmaceutical company, is pleased to announce the TC-002 Phase 3 trial has been successfully initiated. TearClear...